首页 > 最新文献

ESMO Open最新文献

英文 中文
91O Phase I results PI3Ka inhibitor TOS-358 91O I期结果：PI3Ka抑制剂TOS-358
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106233
V. Abramson , B. Doger de Spéville , T.C. Hernandez Guerrero , A. Giordano , J. Bartolomé Arcilla , A. Varkaris , G.M. Wulf , M.A. Salkeni , J.M. Lopez-Picazo Gonzalez , V. Boni , G. Alonso Casal , Z. Goldberg
{"title":"91O Phase I results PI3Ka inhibitor TOS-358","authors":"V. Abramson , B. Doger de Spéville , T.C. Hernandez Guerrero , A. Giordano , J. Bartolomé Arcilla , A. Varkaris , G.M. Wulf , M.A. Salkeni , J.M. Lopez-Picazo Gonzalez , V. Boni , G. Alonso Casal , Z. Goldberg","doi":"10.1016/j.esmoop.2026.106233","DOIUrl":"10.1016/j.esmoop.2026.106233","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106233"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
57TiP PARPA-293-003: Phase Ia/Ib study of NMS-03305293 (Itareparib), a brain-penetrant, non-trapping PARP1-selective inhibitor, in combination with topotecan in recurrent HR proficient platinum-resistant/refractory ovarian cancer 57TiP PARPA-293-003: NMS-03305293 （Itareparib）的Ia/Ib期研究，一种脑渗透，非捕获parp1选择性抑制剂，与拓扑替康联合治疗复发性HR精通铂耐/难治性卵巢癌
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106163
D. Roberti , A. Jazaeri , P.H. Thaker , L.P. Martin , J.S. Russell , S. Westin , S. Maruzzelli , B. Sherer , L. Mahnke , J. Merriman
{"title":"57TiP PARPA-293-003: Phase Ia/Ib study of NMS-03305293 (Itareparib), a brain-penetrant, non-trapping PARP1-selective inhibitor, in combination with topotecan in recurrent HR proficient platinum-resistant/refractory ovarian cancer","authors":"D. Roberti , A. Jazaeri , P.H. Thaker , L.P. Martin , J.S. Russell , S. Westin , S. Maruzzelli , B. Sherer , L. Mahnke , J. Merriman","doi":"10.1016/j.esmoop.2026.106163","DOIUrl":"10.1016/j.esmoop.2026.106163","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106163"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
42P Stage-specific long non-coding RNA signatures in human prostate tissue enhance diagnostic precision and predict aggressive and castration-resistant disease 人类前列腺组织中的42P阶段特异性长链非编码RNA特征可提高诊断精度并预测侵袭性和去势抵抗性疾病
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106147
P. Verma
{"title":"42P Stage-specific long non-coding RNA signatures in human prostate tissue enhance diagnostic precision and predict aggressive and castration-resistant disease","authors":"P. Verma","doi":"10.1016/j.esmoop.2026.106147","DOIUrl":"10.1016/j.esmoop.2026.106147","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106147"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
26eP Trastuzumab deruxtecan in HER2-positive or ERBB2-mutated tumours: Real-world clinical practice data Trastuzumab deruxtecan治疗her2阳性或erbb2突变肿瘤：真实世界的临床实践数据
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106129
N. Rodriguez Macias , M.A. Cordero , J. Montes González , C. Saavedra Serrano , M.L. Sanchez Lorenzo , R. Sanchez Bayona , J. Moreno , L. Montero de la Fuente , A. Gomez de Liano Lista , D. Rodriguez Abreu , P. Soto Rojas , A. Estival Gonzalez , E.G. Guadalupe , N. Karani Narain , J.A.R. Rodríguez García , E.F. Llabres Valenti , G. Visedo Ceballos , M.G. Arevalo , A. Ramchandani Vaswani
{"title":"26eP Trastuzumab deruxtecan in HER2-positive or ERBB2-mutated tumours: Real-world clinical practice data","authors":"N. Rodriguez Macias , M.A. Cordero , J. Montes González , C. Saavedra Serrano , M.L. Sanchez Lorenzo , R. Sanchez Bayona , J. Moreno , L. Montero de la Fuente , A. Gomez de Liano Lista , D. Rodriguez Abreu , P. Soto Rojas , A. Estival Gonzalez , E.G. Guadalupe , N. Karani Narain , J.A.R. Rodríguez García , E.F. Llabres Valenti , G. Visedo Ceballos , M.G. Arevalo , A. Ramchandani Vaswani","doi":"10.1016/j.esmoop.2026.106129","DOIUrl":"10.1016/j.esmoop.2026.106129","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106129"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
50eP Integrated DNA sequencing, transcriptomic and bioinformatic profiling enables precision medicine in prostate cancer 整合DNA测序、转录组学和生物信息学分析使前列腺癌精准医学成为可能
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106155
P. Verma
{"title":"50eP Integrated DNA sequencing, transcriptomic and bioinformatic profiling enables precision medicine in prostate cancer","authors":"P. Verma","doi":"10.1016/j.esmoop.2026.106155","DOIUrl":"10.1016/j.esmoop.2026.106155","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106155"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
58TiP PARPA-293-004: Phase Ib study of NMS-03305293, a brain-penetrant, non-trapping PARP1-selective inhibitor, in combination with temozolomide in relapsed ES-small cell lung cancer PARPA-293-004: NMS-03305293（一种脑渗透、非捕获parp1选择性抑制剂）联合替莫唑胺治疗复发性es -小细胞肺癌的Ib期研究
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106164
D. Roberti , C. Meador , J. Zhang , J. Merriman , S. Maruzzelli , B. Sherer , L. Mahnke , J.S. Russell
{"title":"58TiP PARPA-293-004: Phase Ib study of NMS-03305293, a brain-penetrant, non-trapping PARP1-selective inhibitor, in combination with temozolomide in relapsed ES-small cell lung cancer","authors":"D. Roberti , C. Meador , J. Zhang , J. Merriman , S. Maruzzelli , B. Sherer , L. Mahnke , J.S. Russell","doi":"10.1016/j.esmoop.2026.106164","DOIUrl":"10.1016/j.esmoop.2026.106164","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106164"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
61O First-in-human phase I evaluation of HCB101, a SIRPα–Fc innate checkpoint fusion protein: Safety, pharmacokinetics, and receptor occupancy HCB101（一种SIRPα-Fc先天检查点融合蛋白）的安全性、药代动力学和受体占用的首次人体I期评估
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106202
F. Ning , N. Iannotti , W-H. Cheng , J. Ma , C-C. Lin , Y. Wang , P.M-H. Chang , W. Edenfield , W. Li , T. Zhang , J. Zhang , F. Mo , A. Yu , A. Luk
{"title":"61O First-in-human phase I evaluation of HCB101, a SIRPα–Fc innate checkpoint fusion protein: Safety, pharmacokinetics, and receptor occupancy","authors":"F. Ning , N. Iannotti , W-H. Cheng , J. Ma , C-C. Lin , Y. Wang , P.M-H. Chang , W. Edenfield , W. Li , T. Zhang , J. Zhang , F. Mo , A. Yu , A. Luk","doi":"10.1016/j.esmoop.2026.106202","DOIUrl":"10.1016/j.esmoop.2026.106202","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106202"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
63P Combination of pembrolizumab lenvatinib in treatment of advanced hepatocellular carcinoma pembrolizumab lenvatinib联合治疗晚期肝细胞癌
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106204
Z. Alisher, F.M. Djuraev
{"title":"63P Combination of pembrolizumab lenvatinib in treatment of advanced hepatocellular carcinoma","authors":"Z. Alisher, F.M. Djuraev","doi":"10.1016/j.esmoop.2026.106204","DOIUrl":"10.1016/j.esmoop.2026.106204","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106204"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
21P 52gMn-DOTA immunoPET of FAP-targeting antibodies fap靶向抗体的21p52gmn - dota免疫pet
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106124
K. Barrett , J. Gallant , K. Ott , A. Lebeau , J. Engle
{"title":"21P 52gMn-DOTA immunoPET of FAP-targeting antibodies","authors":"K. Barrett , J. Gallant , K. Ott , A. Lebeau , J. Engle","doi":"10.1016/j.esmoop.2026.106124","DOIUrl":"10.1016/j.esmoop.2026.106124","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106124"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
22P Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A real-world study from the ARON-2EV project ARON-2EV项目的一项真实世界研究表明，接受安替妥单抗维多汀治疗的晚期尿路上皮癌患者骨转移
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106125
A. Rizzo , Z.W. Myint , F. Ciccimarra , A. Zgura Florina , M.R. Matrana , J. Kopecky , K. Fujita , O. Brunetti , D. Santini , S.H. Park , A. Poprach , J. Kucharz , S. Bove , M.C. Comes , R. Massafra , F.S.M. Monteiro , V. Mollica , F. Massari , J. Molina Cerrillo , M. Santoni
{"title":"22P Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A real-world study from the ARON-2EV project","authors":"A. Rizzo , Z.W. Myint , F. Ciccimarra , A. Zgura Florina , M.R. Matrana , J. Kopecky , K. Fujita , O. Brunetti , D. Santini , S.H. Park , A. Poprach , J. Kucharz , S. Bove , M.C. Comes , R. Massafra , F.S.M. Monteiro , V. Mollica , F. Massari , J. Molina Cerrillo , M. Santoni","doi":"10.1016/j.esmoop.2026.106125","DOIUrl":"10.1016/j.esmoop.2026.106125","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106125"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
ESMO Open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1